The emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide and others) now promises effective, non-invasive treatment of obesity for individuals with and without diabetes. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.